Clinical Trials Logo

Esophageal Neoplasms clinical trials

View clinical trials related to Esophageal Neoplasms.

Filter by:

NCT ID: NCT05563766 Not yet recruiting - Clinical trials for Esophageal Squamous Cell Carcinoma

A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer

Start date: July 1, 2024
Phase: Phase 2
Study type: Interventional

Esophageal cancer, which has a low 5-year overall survival rate (<20%) is increasing in incidence. Previous studies have shown that Hedgehog, AKT, and angiogenic signaling pathways are activated in a significant number of esophageal cancers. Itraconazole, a widely used anti-fungal medication, effectively inhibits these pathways. In this multi-site phase II trial, the investigators will evaluate the effect of itraconazole as a neoadjuvant therapy added to standard of care chemoradiation and surgery in the the treatment of locoregional esophageal and gastroesophageal junction cancers.

NCT ID: NCT05542680 Not yet recruiting - Esophageal Cancer Clinical Trials

Study on the Design and Application of Special Semi Recumbent Cushion for Postoperative Patients With Esophageal Cancer

Start date: September 30, 2022
Phase: N/A
Study type: Interventional

1. transform and produce the authorized utility model invention patent "a special cushion for semi recumbent position". 2. to verify the effect of using special semi recumbent cushion for postoperative patients with esophageal cancer.

NCT ID: NCT05504265 Not yet recruiting - Esophageal Cancer Clinical Trials

Perioperative Analgesia Modes in Minimally Invasive Esophagectomy

Start date: August 10, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

This study was designed to compare analgesic efficacy and safety of different perioperative analgesic modes in minimally invasive esophagectomy for esophageal cancer.

NCT ID: NCT05498168 Not yet recruiting - Esophageal Cancer Clinical Trials

Computational Prediction and Experimental Validation of Esophageal Cancer Associated Neoantigens

Start date: September 1, 2022
Phase:
Study type: Observational

This study is to develop computational pipelines and experimental validation assays for improving the identification of neoantigens from patients with esophageal cancer.

NCT ID: NCT05406024 Not yet recruiting - Esophageal Neoplasm Clinical Trials

Feasibility Study CORPPS

FAISA-CORPPS
Start date: September 2022
Phase:
Study type: Observational

The incidence of cancer in France has increased by +135% to reach nearly 400,000 new cases in 2018. The ten-year cancer control strategy 2021-2030 and the health innovation plan have defined strategic axes. Almost all of these axes are addressed in our project. Firstly, the main objective of our study is to improve the quality of life of patients. Secondly, pharyngolaryngeal and oesophageal cancers are among the cancers with a poor prognosis in adults. Thirdly, the project provides access to personalised supportive care for all patients at all times. Finally, the secondary objectives of this study are the prevention of post-operative complications (infectious, thrombo-embolic, pain...).

NCT ID: NCT05387681 Not yet recruiting - Immunotherapy Clinical Trials

Preoperative Short Course Radiotherapy With Envafolimab, Endostatin and SOX Regimen in Locally Advanced Gastric

Start date: May 30, 2022
Phase: Phase 2
Study type: Interventional

This is a single-arm, exploratory clinical study to evaluate the efficacy and safety of Preoperative short course radiotherapy with Envafolimab, Endostatin and SOX regimen in resectable locally advanced gastric/gastroesophageal junction adenocarcinoma.

NCT ID: NCT05296005 Not yet recruiting - Clinical trials for Gastric Adenocarcinoma

Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers

Start date: May 31, 2022
Phase: Phase 1
Study type: Interventional

This phase I trial tests the safety, side effects studies chemotherapy followed by chemotherapy at the same time as radiation therapy (chemoradiation) before surgery (neoadjuvant) in treating patients with stage gastric (stomach) or gastroesophageal junction cancer . Chemotherapy drugs, such as docetaxel, oxaliplatin , leucovorin, fluorouracil, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving chemotherapy and chemoradiation before surgery may make the tumor smaller and may reduce the amount of normal tissue that needs to be removed.

NCT ID: NCT05208775 Not yet recruiting - Clinical trials for Esophageal Carcinoma in Situ AJCC V7

A Comparative Study of Endoscopic Submucosal Dissection and Photodynamic Therapy for Early Esophageal Cancer

Start date: March 1, 2022
Phase: N/A
Study type: Interventional

The purpose of this study was to compare the efficacy and safety of Photodynamic therapy (PDT) and Endoscopic submucosal (ESD) dissection in the treatment of early esophageal cancer.

NCT ID: NCT05183958 Not yet recruiting - Esophageal Cancer Clinical Trials

A Multicenter, Randomized Controlled, Phase II Clinical Study of First-line Chemotherapy and Camrelizumab With or Without Radiotherapy in the Treatment of Oligometastatic Esophageal Cancer

Start date: December 31, 2021
Phase: Phase 2
Study type: Interventional

A multi-center, open, randomized controlled, phase II clinical study to evaluate the efficiency and safety of chemotherapy and immunotherapy combined with locol radiotharepy in treatment of patients with oligometastatic esophageal carcinoma.

NCT ID: NCT05174117 Not yet recruiting - Esophagus Cancer Clinical Trials

Influence of Different Light Dose on the Adverse Effect of Swallowing for Esophageal Carcinoma

Start date: January 1, 2022
Phase: N/A
Study type: Interventional

The purpose of this experiment is to study the alleviating effects and side effects of different laser irradiation doses on esophageal stricture of esophageal cancer in order to find the appropriate dose of light.